Cheng CH, Hao WR, Cheng TH. Fanlian Huazhuo formula: A promising therapeutic approach for metabolic associated steatotic liver disease. World J Gastroenterol 2025; 31(1): 100250 [DOI: 10.3748/wjg.v31.i1.100250]
Corresponding Author of This Article
Tzu-Hurng Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung 404328, Taiwan. thcheng@mail.cmu.edu.tw
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jan 7, 2025; 31(1): 100250 Published online Jan 7, 2025. doi: 10.3748/wjg.v31.i1.100250
Fanlian Huazhuo formula: A promising therapeutic approach for metabolic associated steatotic liver disease
Chun-Han Cheng, Wen-Rui Hao, Tzu-Hurng Cheng
Chun-Han Cheng, Department of Medical Education, Linkou Chang Gung Memorial Hospital, Taoyuan 33305, Taiwan
Wen-Rui Hao, Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Ministry of Health and Welfare, Taipei Medical University, New Taipei 23561, Taiwan
Wen-Rui Hao, Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11002, Taiwan
Tzu-Hurng Cheng, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, Taichung 404328, Taiwan
Co-first authors: Chun-Han Cheng and Wen-Rui Hao.
Author contributions: Cheng CH and Hao WR are co-first authors and have contributed equally to drafting the editorial. Their contributions include the initial writing, literature review, and conceptualization of the editorial content. Cheng TH, as a corresponding author, played a key role in overseeing the revision process, providing critical feedback, and ensuring the editorial's accuracy and coherence; both Cheng CH and Hao WR have made substantial contributions, and their equal roles in the preparation of the manuscript are acknowledged. All authors have read and approved the final manuscript.
Conflict-of-interest statement: All authors declare having no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tzu-Hurng Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung 404328, Taiwan. thcheng@mail.cmu.edu.tw
Received: August 11, 2024 Revised: October 31, 2024 Accepted: November 18, 2024 Published online: January 7, 2025 Processing time: 120 Days and 2.9 Hours
Abstract
This article reviews the study, “Fanlian huazhuo formula alleviates high-fat-diet-induced nonalcoholic fatty liver disease by modulating autophagy and lipid synthesis signaling pathway” published in the World Journal of Gastroenterology. The study explores the therapeutic potential of Fanlian Huazhuo formula (FLHZF) in treating metabolic-associated steatotic liver disease (MASLD), demonstrating that FLHZF reduces lipid accumulation, oxidative stress, and liver injury in MASLD models by modulating key signaling pathways involved in lipid metabolism and autophagy. This editorial emphasizes the potential of FLHZF as a treatment for MASLD and calls for further research to verify its clinical efficacy.
Core Tip: This article highlights the key findings of a study that Fanlian Huazhuo formula (FLHZF) is effective in treating metabolic-associated steatotic liver disease (MASLD) by reducing lipid accumulation, oxidative stress, and liver injury. FLHZF achieves these benefits by modulating autophagy and lipid metabolism pathways. These results underscore FLHZF’s potential as a therapeutic option for MASLD and emphasize the requirement for further clinical trials to validate its efficacy and safety in larger patient populations.
